Research advances in neuroblastoma immunotherapy

Current Pediatric Reviews

Volumn 5, Issue 2, 2009, Pages 112-117

  Booker, Latania Y ^a   Ishola, Titilope A ^a   Bowen, Kanika A ^a   Chung, Dai H ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Antibody mediated therapy; Cell mediated therapy; Cytokine mediated therapy; Immunotherapy; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CYCLOPHOSPHAMIDE; FRACTALKINE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; GANGLIOSIDE GD2 ANTIBODY; GANGLIOSIDE GD3; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; IODINE 131; LYMPHOTACTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; RNA; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4 CD8 RATIO; CELL ACTIVATION; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DOSE COMPARISON; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; IMMUNOGENICITY; LIVER METASTASIS; NATURAL KILLER CELL; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROPATHIC PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR REGRESSION; UPREGULATION; URTICARIA;

EID: 68549136877     PISSN: 15733963     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339609788185686     Document Type: Review

References (73)

1. Society AC. Cancer Facts & Figures 2008. American Cancer Society 2008.
2. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995; 75: 2186-95.
3. Morandi F, Chiesa S, Bocca P, et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia 2006; 8: 833-42.
4. Brodeur GM. Commentary on Kaneko, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 2002; 24: 608-9.
5. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003; 4: 472-80.
6. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
7. Cecchetto G, Mosseri V, De Bernardi B, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23: 8483-9.
8. Kushner BH, Cheung NK. Neuroblastoma - from genetic profiles to clinical challenge. N Engl J Med 2005; 353: 2215-7.
9. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23: 6459-65.
10. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-73.
11. McCune JS, Salinger DH, Vicini P, et al. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. J Clin Pharmacol 2009; 49: 88-102.
12. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007; 25: 67-77.
13. Cheung NK, Kushner BH, Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am 2001; 15: 853-66.
14. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005; 6: 649-58.
15. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 1997; 79: 2028-35.
16. Bestagno M, Occhino M, Corrias MV, Burrone O, Pistoia V. Recombinant antibodies in the immunotherapy of neuroblastoma: perspectives of new developments. Cancer Lett 2003; 197: 193-8.
17. Hellstrom IE, Hellstrom KE, Pierce GE, Bill AH. Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci USA 1968; 60: 1231-8.
18. Hellstrom I, Hellstrom KE, Pierce GE, Yang JP. Cellular and humoral immunity to different types of human neoplasms. Nature 1968; 220: 1352-4.
19. Barker E, Mueller BM, Handgretinger R, et al. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991; 51: 144-9.
20. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994; 91: 9626-30.
21. Cheung N-KV, Cohn SL. Neuroblastoma. Berlin, New York: Springer 2005.
22. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001; 491: 369-402.
23. Svennerholm L, Bostrom K, Fredman P, et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1994; 1214: 115-23.
24. Cheresh DA, Harper JR, Schulz G, Reisfeld RA. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 1984; 81: 5767-71.
25. Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987; 5: 1430-40.
26. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000; 18: 4077-85.
27. Cheresh DA, Rosenberg J, Mujoo K, Hirschowitz L, Reisfeld RA. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res 1986; 46: 5112-8.
28. Saito M, Yu RK, Cheung NK. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Commun 1985; 127: 1-7.
29. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990; 144: 1382-6.
30. Riemer AB, Forster-Waldl E, Bramswig KH, et al. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur J Immunol 2006; 36: 1267-74.
31. Kowalczyk A, Wierzbicki A, Gil M, et al. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery. Cancer Immunol Immunother 2007; 56: 1443-58.
32. Handgretinger R, Baader P, Dopfer R, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992; 35: 199-204.
33. Kushner BH, Cheung IY, Kramer K, Modak S, Cheung NK. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer 2007; 48: 430-4.
34. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989; 73: 1936-41.
35. Munn DH, Cheung NK. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 1987; 47: 6600-5.
36. Saarinen UM, Coccia PF, Gerson SL, Pelley R, Cheung NK. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Res 1985; 45: 5969-75.
37. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009; 27: 85-91.
38. Manzke O, Russello O, Leenen C, et al. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bi-specific antibodies. Med Pediatr Oncol 2001; 36: 185-9.
39. Tur MK, Sasse S, Stocker M, et al. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines. Int J Mol Med 2001; 8: 579-84.
40. Thomas PB, Delatte SJ, Sutphin A, Frankel AE, Tagge EP. Effective targeted cytotoxicity of neuroblastoma cells. J Pediatr Surg 2002; 37: 539-44.
41. Miederer M, McDevitt MR, Borchardt P, et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialoganglioside GD2. Clin Cancer Res 2004; 10: 6985-92.
42. Hoefnagel CA, Rutgers M, Buitenhuis CK, et al. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients. Eur J Nucl Med 2001; 28: 359-68.
43. Hoefnagel CA, Taal BG, Sivro F, Boot H, Valdes Olmos RA. Enhancement of 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG. Nucl Med Commun 2000; 21: 755-61.
44. Kinuya S, Li XF, Yokoyama K, et al. Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma. Eur J Nucl Med Mol Imaging 2003; 30: 1246-50.
45. Armour A, Cunningham SH, Gaze MN, Wheldon TE, Mairs RJ. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer 1997; 75: 470-6.
46. Meco D, Lasorella A, Riccardi A, et al. Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines. Eur J Cancer 1999; 35: 1227-34.
47. Lode HN, Xiang R, Varki NM, et al. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997; 89: 1586-94.
48. Lode HN, Xiang R, Dreier T, et al. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998; 91: 1706-15.
49. Wang KS, Frank DA, Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 2000; 95: 3183-90.
50. Nguyen T, Wang R, Russell JH. IL-12 enhances IL-2 function by inducing CD25 expression through a p38 mitogen-activated protein kinase pathway. Eur J Immunol 2000; 30: 1445-52.
51. Siapati KE, Barker S, Kinnon C, et al. Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer 2003; 88: 1641-8.
52. Barker SE, Grosse SM, Siapati EK, et al. Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12. Br J Cancer 2007; 97: 210-7.
53. Russell HV, Strother D, Mei Z, et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 2007; 30: 227-33.
54. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 1998; 16: 365-96.
55. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld RA. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther 1998; 80: 277-92.
56. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006; 12: 1750-9.
57. Prigione I, Corrias MV, Airoldi I, et al. Immunogenicity of human neuroblastoma. Ann NY Acad Sci 2004; 1028: 69-80.
58. Jaffee EM, Lazenby A, Meurer J, et al. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother Emphasis Tumor Immunol 1995; 18: 1-9.
59. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003; 101: 1718-26.
60. Zeng Y, Huebener N, Fest S, et al. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 2007; 67: 2331-8.
61. Russell HV, Strother D, Mei Z, et al. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother 2008; 31: 812-9.
62. Atzpodien J, Reitz M. GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients. Cancer Biother Radiopharm 2007; 22: 551-5.
63. Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S, et al. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther 2005; 12: 699-707.
64. Caruso DA, Orme LM, Amor GM, et al. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer 2005; 103: 1280-91.
65. Wolfl M, Batten WY, Posovszky C, Bernhard H, Berthold F. Gangliosides inhibit the development from monocytes to dendritic cells. Clin Exp Immunol 2002; 130: 441-8.
66. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16: 1788-94.
67. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-74.
68. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
69. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
70. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
71. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000; 6: 372-80.
72. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61: 8513-9.
73. Wierzbicki A, Gil M, Ciesielski M, et al. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells. J Immunol 2008; 181: 6644-53.